NCT00543712终止2 期
A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Adverse events
研究概览
简要总结
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and willingness to sign a written informed consent document
- •Age ≥ 18 years
- •Histologic diagnosis of chondrosarcoma, verifiable after enrollment
- •Measurable disease
- •Previously treated or incurable disease without options for standard of care therapy
- •ECOG performance status of 0-2
- •Life expectancy of > 3 months
- •For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier) throughout the trial and for 1 year following their final exposure to study treatment
排除标准
- •Systemic therapy or radiotherapy within 4 weeks prior to Day 1
- •Prior therapy with agents targeting the DR5 apoptosis pathway
- •Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
- •Other invasive malignancies within 5 years prior to Day 1
- •Known active brain metastases
- •Uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring parenteral antibiotics at enrollment
- •Clinically significant, symptomatic cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade II or greater peripheral vascular disease, or history of major heart surgery within 6 months of Day 1, or any situation that would likely limit compliance with study requirements
- •Known to be positive for hepatitis C or hepatitis B surface antigen
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
- •Use of anticoagulation therapy
- •Participation in clinical trials or undergoing other investigational procedures within 30 days prior to Day 1
- •Pregnancy or breast feeding
- •Known sensitivity to any of the products administered during the study
- •Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures
研究组 & 干预措施
PRO95780
Experimental
干预措施: PRO95780 (Drug)
结局指标
主要结局
Adverse events
Change in vital signs before and after PRO95780 infusions; clinical laboratory evaluations
Objective response
次要结局
- Duration of objective response
- Progression-free survival
- Overall survival
- Pharmacokinetic parameters
研究者
研究点 (4)
Loading locations...
相似试验
暂停
2 期
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaNCT01982175Shanghai Zhangjiang Biotechnology Limited Company120
已完成
2 期
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT00328198Genzyme, a Sanofi Company86
已完成
2 期
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerLung Cancer, Non-Small CellNCT01362296GlaxoSmithKline134
撤回
2 期
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerCervical CancerNCT05033132Agenus Inc.
撤回
2 期
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04100330AVEO Pharmaceuticals, Inc.